Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Earnest Partners LLC

Earnest Partners LLC increased its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 618,049 shares of the medical research company's stock after buying an additional 12,500 shares during the period. Bio-Rad Laboratories comprises approximately 0.9% of Earnest Partners LLC's holdings, making the stock its 25th largest position. Earnest Partners LLC owned 2.21% of Bio-Rad Laboratories worth $203,035,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Venturi Wealth Management LLC increased its stake in Bio-Rad Laboratories by 2,175.0% during the fourth quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock worth $30,000 after acquiring an additional 87 shares during the last quarter. GeoWealth Management LLC increased its stake in Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock worth $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management lifted its position in shares of Bio-Rad Laboratories by 55.6% during the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares during the last quarter. Asset Planning Inc purchased a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at $33,000. Finally, UMB Bank n.a. grew its holdings in shares of Bio-Rad Laboratories by 41.6% in the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock worth $36,000 after purchasing an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Down 0.8 %

Shares of NYSE:BIO traded down $1.86 during trading on Friday, reaching $238.57. The stock had a trading volume of 448,974 shares, compared to its average volume of 317,557. Bio-Rad Laboratories, Inc. has a one year low of $215.38 and a one year high of $387.99. The firm's 50-day simple moving average is $247.75 and its 200 day simple moving average is $305.85. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $6.68 billion, a P/E ratio of -3.67 and a beta of 1.12.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 EPS for the quarter, beating the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The business had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same period in the prior year, the firm earned $2.30 EPS. The business's revenue for the quarter was down 4.2% on a year-over-year basis. As a group, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. StockNews.com cut shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Wells Fargo & Company reduced their price objective on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Finally, Royal Bank of Canada lowered their target price on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a report on Friday. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $362.40.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.